Last reviewed · How we verify
NCT05311943
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
Phase 3 trial testing olverembatinib in Olverembatinib in 40 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | Shenzhen Second People's Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 July 2022 |
| Primary completion | 30 June 2024 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- olverembatinib — full drug profile →
Conditions studied
- Olverembatinib — all drugs for Olverembatinib →
- Chronic Myeloid Leukemia, Chronic Phase — all drugs for Chronic Myeloid Leukemia, Chronic Phase →
- Tyrosine Kinase Inhibitors — all drugs for Tyrosine Kinase Inhibitors →
Sponsor
Shenzhen Second People's Hospital
Who can join
Adults 18 to 75, any sex, with Olverembatinib or Chronic Myeloid Leukemia, Chronic Phase. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this trial is to evaluate the efficacy and safety of olverembatinib(HQP1351) in patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to at least two second-generation tyrosine kinase inhibitors. The efficacy of olverembatinib is determined by evaluating the major molecular responses(MMR) at the and of 12 months.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Angiogenic signaling pathways and anti-angiogenic therapy for cancer.
Liu ZL, Chen HH, Zheng LL, Sun LP, et al · · 2023 · cited 808× · PMID 37169756 · DOI 10.1038/s41392-023-01460-1 -
The integrated stress response in cancer progression: a force for plasticity and resistance.
Lines CL, McGrath MJ, Dorwart T, Conn CS. · · 2023 · cited 46× · PMID 37601686 · DOI 10.3389/fonc.2023.1206561 -
Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice.
Yang S, Fang Y, Ma Y, Wang F, et al · · 2025 · cited 22× · PMID 40268524 · DOI 10.1002/ctm2.70313 -
A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia.
Qian H, Gang D, He X, Jiang S. · · 2022 · cited 9× · PMID 36568202 · DOI 10.3389/fonc.2022.1036437 -
Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy.
Halder P, Rai A, Talukdar V, Das P, et al · · 2024 · cited 7× · PMID 38784451 · DOI 10.1039/d4md00003j -
Exploring treatment decision-making in chronic myeloid leukemia in chronic phase.
Andorsky D, Kota V, Sweet K. · · 2024 · cited 4× · PMID 39011484 · DOI 10.3389/fonc.2024.1369246 -
Novel targeted therapies in chronic myeloid leukemia.
Ashaq MS, Zhou Q, Li Z, Zhao B. · · 2024 · cited 2× · PMID 41550150 · DOI 10.1016/j.pscia.2024.100052 -
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia.
Irgit A, Kamıs R, Sever B, Tuyun AF, et al · · 2025 · cited 2× · PMID 40346758 · DOI 10.1002/ardp.70005
Verify or expand the search:
- PubMed search for NCT05311943
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of olverembatinib
Trials testing the same drug.
- NCT07178912 — Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromoso · Phase 2 · not yet recruiting
- NCT06817720 — Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chroni · Phase 2 · recruiting
Other recruiting trials for Olverembatinib
Currently open trials in the same condition.
- NCT07282093 — Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment · Phase 1 · recruiting
Other Shenzhen Second People's Hospital trials
Trials by the same sponsor.
- NCT06542016 — An Evaluation of the KCCQ Score in Predicting Cardiovascular Risk in Dialysis Patients · recruiting
- NCT05540808 — The Value of Full-targeted Pathogen Capture Metagenomics Next Generation Sequencing in Etiological Diagnosis of Sepsis · unknown
- NCT05603975 — Analgesic Effect of Esketamine in DCSB in Adultscontrolled Study · NA · unknown
- NCT05465980 — Development and Validation of the Prediction Model for Cognitive Impairment · unknown
- NCT05452759 — Research of Spiral Exhalation Device Oxygen Therapy to Improve the Treatment Effect of Patients With Severe Pneumonia · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05311943 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Second People's Hospital
- Last refreshed: 29 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05311943.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing